Amy Miller
Psychiatry · Saltillo, MSNPI 1265533038
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,275 of the $82,346 with a category attached, or 86.6%. AbbVie accounts for 91.7% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $20,605, 6.1 times the $3,402 reported in 2019. Among psychiatry clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 544 payments — averaging $151.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$75K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Takeda Pharmaceuticals U.S.A., Inc.$767
- Otsuka America Pharmaceutical, Inc.$680
- Teva Pharmaceuticals USA, Inc.$605
- Lundbeck LLC$422
- plus $2K from 17 others
What the payments were for
- Consulting fees$1,7602%
- Speaking & faculty fees$71,27587%
- Travel & lodging$2,3813%
- Food & beverage$6,7818%
- Education$1500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 211 | $75,478 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 75 | $2,830 |
| Takeda Pharmaceuticals U.S.A., Inc. | 57 | $767 |
| Otsuka America Pharmaceutical, Inc. | 41 | $680 |
| Teva Pharmaceuticals USA, Inc. | 39 | $605 |
| Lundbeck LLC | 26 | $422 |
| Alkermes, Inc. | 12 | $230 |
| Johnson & Johnson | 9 | $213 |
| Axsome Therapeutics, Inc. | 16 | $186 |
| Bausch Health US, LLC | 10 | $180 |
| Idorsia Pharmaceuticals US Inc | 7 | $115 |
| Sunovion Pharmaceuticals Inc. | 8 | $94 |
| Tris Pharma Inc | 5 | $79 |
| Supernus Pharmaceuticals, Inc. | 4 | $78 |
| Shire North American Group Inc | 4 | $68 |
| Neurocrine Biosciences, Inc. | 3 | $66 |
| Vanda Pharmaceuticals Inc. | 4 | $65 |
| Neuronetics, Inc. | 4 | $47 |
| Eisai Inc. | 3 | $44 |
| Merck | 2 | $34 |
| Collegium Pharmaceutical, Inc. | 2 | $33 |
| Corium, LLC | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$82,346 in reported general payments places this provider in the 95th percentile of 219 psychiatry providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 13 | $50,993 |
| VraylarCariprazine Hcl | 21 | $31,166 |
| RexultiBrexpiprazole | 12 | $19,987 |
| TrintellixVortioxetine Hydrobromide | 30 | $15,968 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 128 | $7,127 |
| Doxepin Hcl | 42 | $1,575 |
| Vilazodone Hcl | 24 | $1,371 |
| Aripiprazole | 40 | $1,196 |
| Duloxetine Hcl | 63 | $1,039 |
| Lamotrigine | 87 | $1,013 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 38 | $912 |
| Amitriptyline Hcl | 41 | $828 |
| Gabapentin | 58 | $766 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 26 | $766 |
| Fluvoxamine Maleate | 22 | $759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $213 | $50,99313 claims |
| AbbVieVraylar | $75,478 | $31,16621 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $680 | $19,98712 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $767 | $15,96830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 219 psychiatry providers in Mississippi.
Other psychiatry in Saltillo
- Maxie GordonClinton$1.3M
- Kurt BuechlerRidgeland$1.1M
- Chasity TorrenceWhitfield$834K
- Jon JacksonJackson$834K
- John NortonJackson$173K
- Clyde GlennRidgeland$68K
- Krishan GuptaJackson$26K
- Joseph KwentusFlowood$13K
- Mark WebbRidgeland$12K
- Kristen BevillJackson$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.